RU2018119104A - Пиримидиновые композиции, их сверхчистые композиции и соли, способы их получения, и способы их применения для лечения заболеваний и состояний, опосредованных н4-гистаминовым рецептором (h4) - Google Patents

Пиримидиновые композиции, их сверхчистые композиции и соли, способы их получения, и способы их применения для лечения заболеваний и состояний, опосредованных н4-гистаминовым рецептором (h4) Download PDF

Info

Publication number
RU2018119104A
RU2018119104A RU2018119104A RU2018119104A RU2018119104A RU 2018119104 A RU2018119104 A RU 2018119104A RU 2018119104 A RU2018119104 A RU 2018119104A RU 2018119104 A RU2018119104 A RU 2018119104A RU 2018119104 A RU2018119104 A RU 2018119104A
Authority
RU
Russia
Prior art keywords
composition
inhibitors
dosage form
diseases
composition according
Prior art date
Application number
RU2018119104A
Other languages
English (en)
Russian (ru)
Other versions
RU2018119104A3 (enExample
Inventor
Чжицзянь Чжу
Хелен БАРКЕР
Майкл Йидон
Вай ЛЮ
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2018119104A publication Critical patent/RU2018119104A/ru
Publication of RU2018119104A3 publication Critical patent/RU2018119104A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2018119104A 2015-10-26 2016-10-25 Пиримидиновые композиции, их сверхчистые композиции и соли, способы их получения, и способы их применения для лечения заболеваний и состояний, опосредованных н4-гистаминовым рецептором (h4) RU2018119104A (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562246482P 2015-10-26 2015-10-26
US62/246,482 2015-10-26
US201662329091P 2016-04-28 2016-04-28
US62/329,091 2016-04-28
US201662359066P 2016-07-06 2016-07-06
US62/359,066 2016-07-06
PCT/EP2016/075708 WO2017072131A1 (en) 2015-10-26 2016-10-25 Pyrimidine compositions, ultra-pure compositions and salts thereof, methods of making the same, and methods of using the same for treating histamine h4 receptor (h4) mediated diseases and conditions

Publications (2)

Publication Number Publication Date
RU2018119104A true RU2018119104A (ru) 2019-11-28
RU2018119104A3 RU2018119104A3 (enExample) 2020-02-19

Family

ID=57200025

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018119104A RU2018119104A (ru) 2015-10-26 2016-10-25 Пиримидиновые композиции, их сверхчистые композиции и соли, способы их получения, и способы их применения для лечения заболеваний и состояний, опосредованных н4-гистаминовым рецептором (h4)

Country Status (21)

Country Link
US (2) US20170158671A1 (enExample)
EP (1) EP3368528A1 (enExample)
JP (1) JP2018531288A (enExample)
KR (1) KR20180067683A (enExample)
CN (1) CN108602801A (enExample)
AU (2) AU2016344627B9 (enExample)
BR (1) BR112018007765A2 (enExample)
CA (1) CA3001636A1 (enExample)
CL (1) CL2018001092A1 (enExample)
CO (1) CO2018004323A2 (enExample)
EC (1) ECSP18038867A (enExample)
HK (1) HK1252050A1 (enExample)
IL (1) IL258813A (enExample)
MX (1) MX2018005140A (enExample)
PE (1) PE20181364A1 (enExample)
PH (1) PH12018500822A1 (enExample)
RU (1) RU2018119104A (enExample)
SG (1) SG11201802676QA (enExample)
TW (1) TW201729810A (enExample)
WO (1) WO2017072131A1 (enExample)
ZA (1) ZA201802183B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
AU2018349284B2 (en) * 2017-10-09 2023-11-16 428 Pharma BV. New salt and solid state forms of escitalopram
CN114900773A (zh) 2017-12-14 2022-08-12 弗洛设计声能学公司 声泳系统及其操作方法、控制声换能器及声学系统的方法
JP7671275B2 (ja) 2019-08-29 2025-05-01 エランコ・ユーエス・インコーポレイテッド 動物用の抗ｉｌ３１抗体
US12102622B2 (en) 2021-02-10 2024-10-01 Iolyx Therapeutics, Inc. Methods for ophthalmic delivery of roflumilast
US12263160B2 (en) 2021-09-22 2025-04-01 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072548A2 (en) 2001-03-09 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic compounds and their use as histamine h4 ligands.
AU2003272285A1 (en) 2002-09-06 2004-03-29 Janssen Pharmaceutica, N.V. Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
KR101235116B1 (ko) * 2005-10-17 2013-02-20 에스케이케미칼주식회사 광학활성 암로디핀 겐티세이트 염의 제조방법
NL2000323C2 (nl) * 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
JP2008127359A (ja) * 2006-11-22 2008-06-05 Kowa Co アトピー性皮膚炎の予防及び／又は治療剤
HUE039713T2 (hu) * 2012-06-08 2019-02-28 Sensorion H4 receptor inhibitorok tinnitus kezelésére

Also Published As

Publication number Publication date
JP2018531288A (ja) 2018-10-25
US20170158671A1 (en) 2017-06-08
AU2016344627A1 (en) 2018-05-10
TW201729810A (zh) 2017-09-01
AU2020200840A1 (en) 2020-02-27
CL2018001092A1 (es) 2018-08-10
PH12018500822A1 (en) 2018-10-01
PE20181364A1 (es) 2018-08-27
ZA201802183B (en) 2019-02-27
HK1252050A1 (zh) 2019-05-10
AU2016344627B9 (en) 2019-11-28
RU2018119104A3 (enExample) 2020-02-19
CA3001636A1 (en) 2017-05-04
KR20180067683A (ko) 2018-06-20
AU2016344627B2 (en) 2019-11-07
EP3368528A1 (en) 2018-09-05
WO2017072131A1 (en) 2017-05-04
CO2018004323A2 (es) 2018-07-19
CN108602801A (zh) 2018-09-28
MX2018005140A (es) 2018-05-07
US20190135787A1 (en) 2019-05-09
ECSP18038867A (es) 2018-05-31
BR112018007765A2 (pt) 2018-10-23
SG11201802676QA (en) 2018-05-30
IL258813A (en) 2018-06-28

Similar Documents

Publication Publication Date Title
CN105664164B (zh) 使用选择性的bcl-2抑制剂的治疗方法
EP1755561B1 (en) Multi-layer tablet comprising non-steroidal anti-inflammatory drugs decongestants and non-sedating antihistamines
CR20210271A (es) Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso
JP2019503365A5 (enExample)
JP2007332141A (ja) 薬
JP2018531288A5 (enExample)
US11278508B2 (en) Compounded compositions and methods for treating pain
RU99107283A (ru) Не содержащие лактозы, негигроскопичные и безводные фармацевтические препараты дескарбоэтоксилоратадина
US20150202186A1 (en) CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN
US20210322438A1 (en) Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
RS59313B1 (sr) Orvepitant za lečenje hroničnog kašlja
US11737975B2 (en) Compounded compositions and methods for treating pain
WO2005004915A2 (en) Compositions comprising meloxicam
JP2007530620A (ja) メロキシカムを含む組成物
JP2013237709A (ja) Ｐｇｄ２拮抗剤及びヒスタミン拮抗剤からなるアレルギー性鼻炎治療用医薬
JP6062705B2 (ja) 医薬組成物
US20050038018A1 (en) Meloxicam compositions
WO2021074284A1 (fr) Utilisation de nictotinamide mononucléotide (nmn) pour la prevention et/ou le traitement de la polyarthrite rhumatoïde et compositions correspondantes
JP2005263743A (ja) ロイコトリエン産生抑制作用を有する医薬組成物
JP2010195716A (ja) 点鼻睡眠導入剤
Polski et al. Review on analgesic effect of co-administrated ibuprofen and caffeine
JP2010241834A (ja) 医薬組成物
JP4344532B2 (ja) 鼻炎用組成物
JP2022016650A (ja) ロキソプロフェン又はその塩及びビタミンｂ１２類を含有する経口用医薬組成物
WO2016006621A1 (ja) Ｐｇｄ２拮抗剤を含有するアレルギー性疾患に伴う症状の治療用医薬

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20210209